Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.28, compared with -$0.51 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.71.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -$0.87 (+51.9%) for the fiscal year ending Dec 2026, a slowdown from the +54.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.28-612.8% QoQ
- Last fiscal yearDec 2025
- -$1.81+54.2% YoY
- LTMMar 2026
- -$1.71+99.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +45.1% | +64.5% | +19.4 pp |
| 1 year | +54.2% | +51.9% | -2.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.81) USD
- Year-over-year change
- +54.2%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.81) | +54.2% |
| FY2024 | 2024-12-31 | (3.95) | +35.1% |
| FY2023 | 2023-12-31 | (6.09) | +56.7% |
| FY2022 | 2022-12-31 | (14.07) | -890.8% |
| FY2021 | 2021-12-31 | (1.42) | — |
EPS (Basic) vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 EPS (Basic) of -$1.71 is the 8th highest of the 10 companies compared; the peer median is -$1.19.
- Its year-over-year change of +99.8% is the 3rd highest of 10, against a peer median of +32.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $1.73 | +120.0% | — | |
| LTM Mar 2026 | $0.27 | +120.9% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$0.99 | +45.3% | — |
| LTM Mar 2026 | -$1.09 | +26.8% | — | |
| LTM Mar 2026 | -$1.19 | +6.4% | — | |
| LTM Mar 2026 | -$1.24 | +10.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$1.31 | +32.5% | — |
| LTM Mar 2026 | -$1.71 | +99.8% | — | |
| LTM Mar 2026 | -$1.87 | +3.6% | — | |
| LTM Mar 2026 | -$5.18 | +48.1% | — | |
| Peer median (excluding INO) | -$1.19 | +32.5% | — | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| Weighted Avg Shares | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
| Weighted Avg Shares (Diluted) | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.